Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.
C erebral amyloid-β aggregation is an early pathologic event in Alzheimer disease (AD), starting 2 to 3 decades before dementia onset. 1, 2 Approximately 25% of cognitively normal elderly individuals and 50% of patients with mild cognitive impairment (MCI) have biomarker evidence of amyloid pathology. 1, 3 These persons are at increased risk for developing AD-type dementia, 1 but the extent to which amyloid-β aggregation is associated with cognition in persons without dementia is unclear. Understanding the association between amyloid pathology and cognitive functioning is important for a better understanding of the course of AD and for the design of AD-prevention trials.
Longitudinal cohort studies [4] [5] [6] have revealed an association between the presence of amyloid pathology and long-term cognitive decline. To assess the role of cognitive screening as a tool to enrich AD clinical trials, the cross-sectional association also needs to be established. However, findings from cross-sectional studies in cognitively normal individuals 4, 7, 8 and patients with MCI 7,9,10 have been inconsistent. This variability may be caused by differences among studies in demographic and genetic factors, disease stage and reserve capacity, and methodologic approaches. Effects are mainly observed in the episodic memory and global cognition domains and tend to be small, 11 indicating that large samples are needed to investigate the amyloidcognition association. We previously estimated the prevalence of amyloid positivity in persons without dementia and, in the present study, investigated the association between amyloid positivity and cognitive scores in this population by using individual participant data from 53 studies included in the multicenter Amyloid Biomarker Study. 1 We also examined whether age, cognitive status, sex, educational level, and apolipoprotein E (APOE) genotype modify the association between amyloid status and global cognition or episodic memory; estimated temporal associations among amyloid positivity, low memory scores, and AD-type dementia; and tested the usefulness of cognitive scores as a screening instrument for amyloid positivity.
Methods

Participants
Participants were recruited from studies that participated in the multicenter Amyloid Biomarker Study 1 on establishing the prevalence of amyloid pathology measured with a positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarker. For details on study selection and data collection, see Jansen et al. 1 Study inclusion began in 2012 and is ongoing. At time of analysis (January 2017), we included participantlevel data from 2908 participants with normal cognition and 4133 patients with MCI from 53 studies that had data available on the Mini-Mental State Examination (MMSE) and/or an episodic memory score. Participants with normal cognition had no cognitive concerns for which medical help was sought and scored within the normal range on cognitive tests. The diagnosis of MCI was made according to published criteria, including subjectively experienced and objectively verified decline in memory or another cognitive domain. Characteristics of the included studies are given in eTable 1 in the Supplement. All participants gave written informed consent to participate, and data were deidentified. Study protocols were approved by the local ethics committees of all centers participating in the Amyloid Biomarker Study.
Cognitive Tests
Global cognition was assessed with the MMSE. 12 The MMSE scores were available from 53 studies comprising a total of 2885 participants with normal cognition (38 studies) and 4133 patients with MCI (48 studies). A low MMSE score was defined as 27 or less. Episodic memory was assessed with verbal word learning tests. Data were available from 31 studies including 2010 participants with normal cognition (21 studies) and 2615 patients with MCI (26 studies). Most studies provided raw scores (28 studies) that were transformed into z scores using the mean and SD of the center-specific group of cognitively unimpaired individuals or, in the absence of such a group, using published test-specific means. Three studies provided z scores that were calculated similarly. Episodic memory was assessed using 12 different verbal memory tests of immediate or delayed recall. When multiple memory test scores were provided for a participant, the delayed recall score was chosen. Tests of delayed recall were used for 2809 participants (21 studies) and tests of immediate recall for 1816 participants (10 studies). See eTable 2 in the Supplement foranoverview of the memory tests used in each study. In our analyses, low episodic memory performance was defined as a z score of −1.28 or less, capturing performance in the 10th percentile or lower of the population mean.
Amyloid Assessment
In the sample selected for these analyses, amyloid pathology was assessed with amyloid-PET in 1224 participants with normal cognition (21 studies) and 956 patients with MCI (23 studies) and by amyloid-β1-42 level in CSF in 1684 participants with normal cognition (19 studies) and 3177 with MCI (29 studies). Measurement details have been described previously. 1 The PET and CSF biomarkers were dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs or visual reads.
Data Availability
Information on the level of education was available for 2558 participants (88.0%) with normal cognition (memory score: n = 1973; MMSE: n = 2536) and 3270 patients (79.1%) with MCI (memory score: n = 2456; MMSE: n = 3264). Information on APOE-ε4 carrier status (yes or no) was available for 2400 participants (82.5%) with normal cognition (memory score: n = 1764; MMSE: n = 2379) and 3292 patients (79.7%) with MCI (memory score: n = 2217; MMSE: n = 3286). The APOE genotype was available for 2347 participants (80.7%) with normal cognition (memory score: n = 1763; MMSE: n = 2326) and 3019 patients (73.0%) with MCI (memory score: n = 2215; MMSE: n = 3013).
Temporal Association Among Amyloid Positivity, Low Memory Scores, and AD-Type Dementia
To provide an estimation of the temporal associations among amyloid positivity, low memory scores, and AD-type dementia, we compared age-specific frequency estimates of low memory scores and amyloid positivity in participants with normal cognition with age-specific prevalence data of AD-type dementia in the general population (adopted from Jansen et al 1 ).
Cognitive Screening as an Indication of Amyloid Status
To investigate the screening potential of low cognitive scores, we calculated the odds of low cognitive performance for amyloid positivity and examined improvement in area under the receiver operating characteristic curve when cognitive scores were added to a model with age and APOE-ε4 carrier status.
Statistical Analysis
Differences in clinical and demographic characteristics between the amyloid-positive and amyloid-negative subgroups were analyzed using analyses of variance for continuous variables and χ 2 tests for categorical variables. Dichotomized MMSE and memory scores (low vs normal) were used as outcome variables in generalized estimating equations. Generalized estimating equations allow for the analysis of binary correlated Model with terms for age, amyloid status, cognitive status, and up to 3-way interactions among these terms (3-way interaction P = .007), APOE genotype, and interactions among APOE genotype, amyloid status, and cognitive status (P = .02). Adjustment for sex and educational level did not change the model. Low score was defined as 10th percentile or lower of z scores.
female [46.2%]) participated in the study. Sample characteristics of the participants with normal cognition and MCI according to amyloid status are given in Table 1 . The amyloid-positive and amyloid-negative groups differed on all variables except sex in participants with normal cognition and MCI and except MMSE score in participants with normal cognition.
Association Between Amyloid Status and Episodic Memory Score
Amyloid positivity was differentially associated with low memory scores across age and diagnostic groups (3-way interaction; β = −0.54 [95% CI, −0.097 to −0.011]). In participants with normal cognition, low memory scores were more frequent in amyloid-positive than in amyloid-negative participants but only after 70 years of age (mean difference for amyloid-positive vs amyloid-negative participants at 72 years of age, 4% [95% CI, 0%-7%], P = .04; at 90 years of age, 21% [95% CI, 10%-33%], P < .001).
At 80 years of age, the frequency of low memory scores in amyloid-positive participants with normal cognition was almost double that of their amyloid-negative counterparts (25% vs 14%) ( Figure 1A and Table 2 ). In patients with MCI, amyloid-positive participants more often had low memory scores than amyloidnegative participants (mean difference, 16% [95% CI, 12%-20%], Prevalence estimates of amyloid positivity and low memory score were derived from separate models including age as a predictor. Prevalence estimates of AD-type dementia were derived from a meta-analysis of 14 studies. 1 Low score was defined as 10th percentile or lower of z scores. P < .001) ( Figure 1B and Table 2 ), although this difference decreased with advancing age.
In participants with normal cognition and patients with MCI, sex, educational level, and APOE-ε4 carrier status were each associated with memory scores but did not moderate the association between amyloid status and memory scores (eFigure1AintheSupplement) . A low memory score was more frequent in men than in women (mean difference, 8% [95% CI, 3%-14%], P = .004), in participants with low rather than high educational level (mean difference, 8% [95% CI, 5%-11%], P < .001), and in APOE-ε4 carriers than in noncarriers (mean difference, 8% [95% CI, 4%-11%], P < .001).
Furthermore, APOE genotype was associated with low memory score independent of amyloid status, cognitive status, or age (Figure 2) . Participants with the APOE-ε4ε4 genotype most often had a low memory score (mean difference vs ε2ε4/ε3ε4, 10% [95% CI, 4%-16%], P < .001; vs ε3ε3, 16% [95% CI, 9%-24%], P < .001; vs ε2ε2/ε2ε3, 21% [95% CI, 9%-24%], P < .001), followed by participants with the APOE-ε2ε4/ε3ε4 genotype (mean difference vs ε3ε3, 6% [95% CI, 3%-9%], P < .001; vs ε2ε2/ε2ε3, 11% [95% CI 4%-17%], P = .001) and the APOE-ε3ε3 and APOE-ε2ε2/ε2ε3 genotypes (mean difference, 5% [95% CI, −1% to 10%], P = .09).
Association Between Amyloid Status and MMSE Score
The association between amyloid positivity and a low score on the MMSE was dependent on age (β = 0.023 [95% CI, 0.009-0.037, P = .001 for interaction) and cognitive status (β = 0.348 [95% CI, 0.032-0.665], P = .03 for interaction; β = 0.006 [95% CI, −0.033 to 0.044], P = .10 for 3-way interaction). In participants with normal cognition, amyloid positivity was not associated with low MMSE scores at any age (mean difference, 3% [95% CI, −1% to 6%], P = .16) ( Figure 1C and Table 2 ). In patients with MCI, the frequency of low MMSE scores was greater in amyloid-positive compared with amyloid-negative patients at all ages (mean difference, 14% [95% CI, 12%-17%], P < .001) ( Figure 1D and Table 2 ).
When adjusting for sex, educational level, and APOE-ε4 carrier status, none of these factors modulated the association between amyloid status and MMSE score in participants with normal cognition or patients with MCI. APOE-ε4 carriership was more often associated with low MMSE scores regardless of cognitive status and age (mean difference, 4% [95% CI, 2%-7%], P < .001). Sex (β = −0.444 [95% CI, −0.681 to −0.207; P<.001 for interaction) and educational level (β = −0.554 [95% CI, −0.874 to −0.234], P<.001 for interaction) had an association with MMSE score that was dependent on cognitive status (eFigure 1B in the Supplement).
In addition, APOE genotype was associated with low MMSE score (P = .002) (eFigure 2 in the Supplement) independent of amyloid status, cognitive status, and age. Participants with the APOE-ε4ε4 genotype most often had a low MMSE score (mean difference vs ε2ε4/ε3ε4, 6% [95% CI, 0%-12%], P = .06; vs ε3ε3, 10% [95% CI, 3%-16%], P = .005; vs ε2ε2/ε2ε3, 10% [95% CI, 3%-16%], P = .005) followed by participants with the APOE-ε2ε4/ε3ε4 genotype (mean difference vs ε3ε3, 4% [95% CI, 1%-6%], P = .008; vs .03
Abbreviations: MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination.
a Data are estimated probabilities uncorrected for sex, educational level, and apolipoprotein E ε4 carrier status. The model for memory included terms for age, amyloid status, cognitive status, and interactions among these terms (3-way interaction P = .002). The model for MMSE included terms for age, amyloid status, cognitive status, and interactions between amyloid status and age (P = .02), and between amyloid status and cognitive status (P < .001). Adjustment for sex and educational level did not change the models. Low score was defined as 10th percentile or lower of z scores for the low memory score and 27 or lower for low MMSE scores. ε2ε2/ε2ε3, 4% [95% CI, 1%-8%], P = .14) and the APOE-ε3ε3 and APOE-ε2ε2/ε2ε3 genotypes (mean difference, 0% [95% CI, −4% to 4%], P = .99).
Association of Cerebral
Amyloid Positivity, Low Memory Scores, and AD-Type Dementia
In participants with normal cognition, the age-related increase in low memory scores paralleled the age-related increase in amyloid positivity with an intervening period of 10 to 15 years. Subsequently, the age-related increase in low memory score was paralleled by an age-related increase in prevalence of AD-type dementia 10 to 15 years later ( Figure 3 ).
Cognitive Screening as an Indication of Amyloid Status
The odds ratio of low memory score for amyloid positivity varied depending on age from 1.06 to 1.80 for participants with normal cognition and from 1.47 to 2.81 for patients with MCI. The odds ratio of low MMSE score varied from 0.77 to 1.19 for participants with normal cognition and from 1.32 to 2.15 for patients with MCI (eTable 4 in the Supplement). The receiver operating characteristic curve analyses showed that low memory or MMSE scores did not add to the estimation of amyloid positivity above that of age and APOE-ε4 carrier status (eTable 5 in the Supplement).
Discussion
In this cross-sectional analysis of adults without dementia enrolled from multiple studies, amyloid pathology was associated with low memory scores among cognitively normal individuals older than 70 years and in patients with MCI until old age, whereas it was associated with low MMSE scores in patients with MCI only. However, a low cognitive score had limited value as a screening measure for early AD. The association between amyloid pathology and cognition existed independent of sex, educational level, and APOE genotype, but these factors contributed to individual estimates of cognitive level. We further observed 10-to 15-year intervals between the onset of amyloid positivity and emergence of low memory scores in persons with normal cognition and between the agerelated increase in low memory scores and prevalence of ADtype dementia. Of note, the proportion of low memory scores in amyloidpositive participants with normal cognition increased rapidly after the age of 70 years. Possible explanations for this age association are that more extensive amounts of amyloid deposition are needed before becoming clinically manifest, that other pathology is also present after this age, or that cognitive vulnerability to amyloid pathology may be higher at older age. This finding agrees with a recent population-based study 13 in cognitively normal individuals aged 50 to 69 years in which amyloid-PET levels were unrelated to cross-sectional and longitudinal measures of episodic memory. Previous contrasting findings from cross-sectional studies 4, 7, 8 that examined the amyloid-cognition association may therefore, in addition to the previously identified task complexity, 14 be explained by age of the individuals in the study sample.
We found no association of amyloid pathology with low MMSE score in participants with normal cognition. This result contrasts with a meta-analysis of biomarker and neuropathologic studies.
11 However, that meta-analysis also included global cognition tests that have a larger memory component than the MMSE. In patients with MCI, amyloid-positive patients had (depending on age) low memory and MMSE scores 5% to 20% more often than amyloid-negative patients. Unlike in participants with normal cognition, frequencies of low cognitive scores in amyloid-positive and amyloid-negative patients were more similar at older ages in patients with MCI. This finding is in line with a study in persons with dementia, 15 suggesting that neuropathologic changes other than amyloid may contribute to cognitive impairment at more advanced age in patients with MCI but not in persons with normal cognition. Sex and amyloid pathology independently predicted cognitive performance, suggesting that amyloid-related cognitive decline is equally prevalent in men and women, as has also been suggested in a large cross-sectional study 16 of cognitively normal individuals from the general population not included in our study. High educational level was also associated with fewer cognitive deficiencies independent of amyloid status. This finding is consistent with earlier studies 17, 18 showing that cognitive reserve helps to preserve cognition in pathologic conditions and aging. Our study suggests that a high educational level does not counteract the effect of amyloid pathology on cognition but instead delays its expression, which agrees with earlier studies.
19,20
Each APOE-ε4 allele increased the risk of low cognitive performance independent of amyloid status. Previous longitudinal studies examining the association among APOE-ε4, amyloid positivity, and cognition have had mixed results and identified mediating 8, 21 or interactive effects. [22] [23] [24] Remarkably, our results indicate that the APOE genotype was also associated with cognitive performance in amyloid-negative participants. This finding may relate to subthreshold pathologic aggregation 25, 26 or to the association of APOE-ε4 genotype with non-amyloid-dependent processes in the brain that are associated with cognitive functioning.
27
This study has implications for understanding the individual contributions of amyloid pathology and various AD risk factors to cognitive decline and the time course of AD. Therefore, these findings are important for the design of secondary AD prevention trials. Because amyloid positivity has become a requirement for enrollment in many AD prevention trials, cognitive testing would be an inexpensive and noninvasive alternative to screen for amyloid positivity. Our study showed that a low cognitive score for screening of amyloid positivity had only limited utility. Cognitive screening efficiency may be improved by more sensitive neuropsychological tests or test norms based on cognitively normal persons without amyloid pathology. The latter is supported by our finding that amyloid pathology appeared to explain a substantial part of the socalled age-related memory decline (Figure 3) . However, cognitive measures can serve as an additional source of enrichment to optimize clinical trial design as has already been implemented in a prevention study. 
Limitations
This study has several methodologic limitations. There were several sources of variance among the pooled studies, including differences in amyloid assessment methods, participant selection, and other aspects of study design. However, the association of these differences with amyloid positivity was modest, 1 and the association of amyloid status with cognitive performance was independent of biomarker modality. Furthermore, the type of memory test differed across studies but did not affect the association between amyloid and cognitive performance. Another potential limitation is that amyloid pathology might be associated with decline in other cognitive domains, such as executive functioning, 8,11 that were not assessed in this study. Furthermore, the power to detect an association between amyloid positivity and MMSE score in participants with normal cognition was limited by the restricted range of MMSE scores in this group. In addition, because our findings were based on research or memory clinic populations, results may not be generalizable to the overall population or other settings. Last, our findings are based on cross-sectional data, which might not accurately reflect individual trajectories of amyloid-related cognitive decline.
Conclusions
Although low memory scores are an early marker of amyloid positivity, their value as a screening measure for early AD among persons without dementia is limited. The ORs were generated from generalized estimating equations separately ran in subgroups without correction for age. P-values represent the significance of the OR for amyloid positivity in participants with low cognitive performance compared to participants without low cognitive performance. OR=odds ratio. CI=confidence interval. MMSE=mini mental state examination. APOE=apolipoprotein E. The AUCs were generated from ROC analyses separately ran in participants with normal cognition and patients with MCI. The model without cognitive score included terms for age and APOE-4 carrier status. 
B. Improvement in area under the receiver operating characteristic (ROC) curve
Methods
In secondary analyses, we repeated the analyses using linear mixed models with continuous episodic memory zscore and continuous MMSE score as outcome measures and using z-scores of -1 and -1.5 as cut-offs for low memory score to examine the impact of memory score cut-off. We compared the pattern of results by inspecting significant main and interaction terms. Further, we examined model fit and possible effects of missing data. We also tested the influence of memory test type and biomarker modality on the association of amyloid pathology with cognition. To examine whether study-specific inclusion criteria that were based on memory or MMSE score influenced the results, we repeated the analyses after excluding studies that selected participants with normal cognition based on the memory score used in our analyses or on MMSE score.
Results
Model-estimated frequencies of low memory score and low MMSE score at age 50 to 90 (Table 2) were similar to the observed frequencies (Supplement, table 5) indicating good model fit. When continuous scores of episodic memory and MMSE were used as the outcome of our analyses, results remained essentially the same (Supplement, figure 3 ). Also, when low memory was defined as z-score≤ -1 (normal cognition: n=355, MCI: n=1752) or as z-score≤ -1.5 (normal cognition: n=143, MCI: n=1333) results were similar (3-way interaction, p=0.03 resp. p=0.006). In participants with missing educational (17.0%) or APOE-4 (19.3%) data, the relationship between amyloid positivity and low cognitive score did not differ from participants with these data. The biomarker used to assess amyloid positivity (PET versus CSF) did not alter the association of amyloid status with low memory (p=0.78) or MMSE score (p=0.11). Memory test type (delayed or immediate recall) did not affect the association of amyloid status to low memory score (p=0.44) in participants with normal cognition or patients with MCI. Results were unchanged after a. excluding 3 studies that used only the scores on the memory measure that was used in our analyses to select participants with normal cognition (p-value 3-way interaction=0.001), b. excluding 6 studies that only included participants with an MMSE> 27 (mean difference amyloid positive vs. negative 2%, 95% CI -1%-6%, p=0.25) and c. excluding all 15 studies that used MMSE to select participants (mean difference amyloid positive vs. negative 3%, 95% CI -2%-8%, p=0.20).
eAppendix 2. ADNI Protocol and DCN Information
ADNI Protocol
Part of the data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). Determination of sensitive and specific markers of very early AD progression is intended to aid researchers and clinicians to develop new treatments and monitor their effectiveness, as well as lessen the time and cost of clinical trials. The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California -San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and ADNI-2. To date these three protocols have recruited over 1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal older individuals, people with early or late MCI, and people with early AD. The follow up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For upto-date information, see www.adni-info.org.
German Dementia Competence Network (DCN) information
The German Dementia Competence Network (DCN) was launched in 2002 by 14 academic centers of excellence in Germany, and was funded by the German Federal Ministry for Education and Research (BMBF) by €25 million over 5 years. The primary goals of DCN are: 1.) to establish procedures for standardized multicenter acquisition of clinical, biological and imaging data, for centralized data management, and for the evaluation of new treatments 2.) to investigate the genetic contribution to different dementias and its effect on phenotypes and course of disease (PI: Wolfgang Maier) 3.) to test whether magnetic resonance imaging (MRI), and/or CSF-and blood-based biological markers, as well as clinical and neuropsychological assessments can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD) over three years. Specifically, sensitive and specific markers of very early AD progression should be developed and evaluated (PI: Johannes Kornhuber). 4.) to test whether a combination therapy between AChE inhibitor and memantine is clinically meaningful in early Alzheimer's disease. Specifically, 2 clinical trials were conducted with patients suffering from MCI and mild to moderate Alzheimer's Disease (AD). These trials have evaluated the efficacy and safety of galantamine and memantine in combination versus galantamine alone (AD) or placebo (MCI) (PI: Isabella Heuser, Lutz Frölich).
The Executive Head of the DCN is Wolfgang Maier, MD, University of Bonn, Germany, the DCN governing board consists of eight PI's from academic institutions. The DCN achieved to recruit over 2000 subjects across Germany, with cognitive impairment of various degree and etiology. To date this cohort, aged 55 to 90 at start, was followed-up by three yearly assessments, a follow-up of 10 years is currently ongoing. A biomaterial, imaging and clinical data bank is in place and is managed for data mining. Figures results from linear mixed models with either memory z-score or MMSE score as outcome measure. The models were specified with a random intercept with an identity covariance structure. The model for Figures 3a and 3b included terms for age, amyloid status, and cognitive status, and up to 3-way interactions between these terms (3-way interaction p<0.0001). 
